FindTrial
Sign In

Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): Very Early Rheumatoid Arthritis (VERA)

Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): Very Early Rheumatoid Arthritis (VERA) - TRACER/VERA

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39332
Enrollment
128
Registered
2013-05-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Sponsors

Center for Translational Molecular Medicine
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18-70 yrs - Arthralgia - Rheumatoid factor or aCCP positive or a first degree relative with rheumatoid arthritis.

Exclusion criteria

Exclusion criteria: - arthritis, established by a rheumatologist - other cause for arthralgia, such as ostheoarthritis, metabolic syndromes etc. - received treatment with Disease Modifying Anti Rheumatic drugs previously - received prednisone treatment, except from cortical or intranasal application, in the last 6 weeks for inclusion.

Design outcomes

Primary

MeasureTime frame
Primary endpoint will be to develop a test or algorithm of multiple tests to predict the development of RA in patients at risk.—

Secondary

MeasureTime frame
Costeffectiveness of the (combination of) different tests compared to the already existing tests, such as aCCP and RF.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)